Tyra Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TYRA Nasdaq 8731 https://tyra.bio/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tyra Biosciences Inc

Tyra Biosciences to Participate in Upcoming Investor Conferences - May 25th, 2023 12:00 pm
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing' - May 23rd, 2023 12:50 pm
Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade - May 22nd, 2023 1:55 pm
Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation - Apr 9th, 2023 1:30 pm
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA) - Mar 27th, 2023 12:50 pm
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights - Mar 22nd, 2023 8:05 pm
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings? - Mar 1st, 2023 1:40 pm
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia - Mar 1st, 2023 12:00 pm
Tyra Biosciences to Present at Upcoming Investor Conferences - Feb 22nd, 2023 9:05 pm
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300 - Nov 29th, 2022 12:00 pm
How Much Upside is Left in Tyra Biosciences, Inc. (TYRA)? Wall Street Analysts Think 184% - Nov 24th, 2022 2:55 pm
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 179%: Read This Before Placing a Bet - Nov 8th, 2022 2:55 pm
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights - Nov 3rd, 2022 8:05 pm
Tyra Biosciences Announces Planned Chief Financial Officer Transition - Nov 2nd, 2022 8:05 pm
We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth - Oct 31st, 2022 1:22 pm
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Oct 13th, 2022 12:00 pm
Tyra Biosciences to Participate at September 2022 Investor Conferences - Sep 8th, 2022 8:05 pm
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress - Sep 5th, 2022 12:15 pm
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights - Aug 4th, 2022 8:05 pm